|Title||Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor.|
|Publication Type||Journal Article|
|Year of Publication||2016|
|Authors||Kong, L, Ju, B, Chen, Y, He, L, Ren, L, Liu, J, Hong, K, Su, B, Wang, Z, Ozorowski, G, Ji, X, Hua, Y, Chen, Y, Deller, MC, Hao, Y, Feng, Y, Garces, F, Wilson, R, Dai, K, O'Dell, S, McKee, K, Mascola, JR, Ward, AB, Wyatt, RT, Li, Y, Wilson, IA, Zhu, J, Shao, Y|
|Date Published||2016 Apr 5|
VRC01-class antibodies neutralize diverse HIV-1 strains by targeting the conserved CD4-binding site. Despite extensive investigations, crucial events in the early stage of VRC01 development remain elusive. We demonstrated how VRC01-class antibodies emerged in a Chinese donor by antigen-specific single B cell sorting, structural and functional studies, and longitudinal antibody and virus repertoire analyses. A monoclonal antibody DRVIA7 with modest neutralizing breadth was isolated that displayed a subset of VRC01 signatures. X-ray and EM structures revealed a VRC01-like angle of approach, but less favorable interactions between the DRVIA7 light-chain CDR1 and the N terminus with N276 and V5 glycans of gp120. Although the DRVIA7 lineage was unable to acquire broad neutralization, longitudinal analysis revealed a repertoire-encoded VRC01 light-chain CDR3 signature and VRC01-like neutralizing heavy-chain precursors that rapidly matured within 2 years. Thus, light chain accommodation of the glycan shield should be taken into account in vaccine design targeting this conserved site of vulnerability.